Who are MK0928, gaboxadol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): total intravenous anesthetics, Intravenous anesthetic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mk0928-gaboxadol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

MK0928, gaboxadol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MK0928, gaboxadol (MK0928, gaboxadol) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GABA-A receptor agonist. Area: Neurology / Sleep Medicine.

phase 3 GABA-A receptor agonist GABA-A receptor (delta subunit-containing) Neurology / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

MK0928, gaboxadol (MK0928, gaboxadol) — H. Lundbeck A/S. Gaboxadol is a selective GABA-A receptor agonist that enhances inhibitory neurotransmission in the central nervous system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MK0928, gaboxadol TARGET	MK0928, gaboxadol	H. Lundbeck A/S	phase 3	GABA-A receptor agonist	GABA-A receptor (delta subunit-containing)
total intravenous anesthetics	total intravenous anesthetics	Università Vita-Salute San Raffaele	marketed	GABA-A receptor agonist / General anesthetic	GABA-A receptor
Intravenous anesthetic	Intravenous anesthetic	University of Pennsylvania	marketed	GABA-A receptor agonist / NMDA receptor antagonist (class-dependent)	GABA-A receptor or NMDA receptor (varies by specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GABA-A receptor agonist class)

H. Lundbeck A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MK0928, gaboxadol — Competitive Intelligence Brief. https://druglandscape.com/ci/mk0928-gaboxadol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab